One-week once-daily triple therapy with esomeprazole, moxifloxacin, and rifabutin for eradication of persistent Helicobacter pylori resistant to both metronidazole and clarithromycin

Helicobacter
Stephan MiehlkeNorbert Lehn

Abstract

To investigate a 1-week once-daily triple therapy with esomeprazole, moxifloxacin, and rifabutin for rescue therapy of Helicobacter pylori infection. Consecutive patients (n = 103) with at least one previous treatment failure and H. pylori infection resistant to both metronidazole and clarithromycin were treated with esomeprazole 40 mg, moxifloxacin 400 mg, and rifabutin 300 mg, given once daily for 7 days. Eradication was confirmed by histology and culture. CYP2C19 status was determined by polymerase chain reaction-restriction fragment length polymorphism. Intention-to-treat and per-protocol eradication rates were 77.7% (68.4-85.3) and 83.3% (74.4-90.2). Five patients discontinued prematurely (4.8%). Eradication was achieved in 93.1% of poor/intermediate metabolizers and in 78.8% of homozygous extensive metabolizers (p = .14). Eradication rates in patients with one, two, three, and four or more previous failures were 78.3%, 89.6%, 68.6%, and 88.9%, respectively (p = .21). The regimen was effective in seven of nine patients who previously failed quadruple therapy. Post-treatment resistance to moxifloxacin and rifabutin was detected in two (12.5%) and five (31%) patients after treatment failure. Once-daily triple therapy with es...Continue Reading

References

Jul 27, 1999·Archives of Internal Medicine·M B FennertyM Helfand
Sep 1, 2000·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·M HeepN Lehn
May 5, 2001·Expert Opinion on Pharmacotherapy·J M Blondeau, G T Hansen
Feb 28, 2002·Alimentary Pharmacology & Therapeutics·P MalfertheinerUNKNOWN European Helicobacter Pylori Study Group (EHPSG)
Mar 6, 2002·Alimentary Pharmacology & Therapeutics·S Di CaroA Gasbarrini
Jul 30, 2002·Alimentary Pharmacology & Therapeutics·P Della MonicaA Pera
Oct 11, 2003·Alimentary Pharmacology & Therapeutics·H LamouliatteUNKNOWN Multicentre Study Group
May 11, 2005·Alimentary Pharmacology & Therapeutics·E C NistaA Gasbarrini
Nov 5, 2005·Alimentary Pharmacology & Therapeutics·J P GisbertJ M Pajares
Aug 19, 2006·Expert Opinion on Investigational Drugs·Andrea MorgnerStephan Miehlke
Oct 18, 2006·Antimicrobial Agents and Chemotherapy·Erik GlockerManfred Kist

❮ Previous
Next ❯

Citations

Jul 19, 2008·Irish Journal of Medical Science·B J EganC A O'Morain
May 1, 2008·Nature Clinical Practice. Gastroenterology & Hepatology·David Y Graham, Akiko Shiotani
Oct 1, 2009·Journal of Gastroenterology and Hepatology·K Ming FockUNKNOWN Second Asia-Pacific Conference
Jul 22, 2009·Antimicrobial Agents and Chemotherapy·Morris O MakobongoD Scott Merrell
Jun 23, 2011·Therapeutic Advances in Gastroenterology·Marco BerningStephan Miehlke
Sep 29, 2011·Current Opinion in Gastroenterology·Michael Selgrad, Peter Malfertheiner
Nov 5, 2013·Journal of Women's Health·Elisa Chilet-RosellMa Angeles Pardo
Jul 18, 2009·Der Internist·W Fischbach
Mar 17, 2011·Journal of Pediatric Gastroenterology and Nutrition·A SchwarzerUNKNOWN ESPGHAN Working Group on Helicobacter pylori Infection
Aug 9, 2011·Expert Review of Anti-infective Therapy·Michael SelgradPeter Malfertheiner
Aug 18, 2009·Expert Review of Anti-infective Therapy·Olaf Burkhardt, Tobias Welte
Aug 30, 2012·Expert Review of Gastroenterology & Hepatology·Mario M D'EliosDomenico Prisco
Oct 23, 2015·Postgraduate Medicine·Frank J SenatoreJohn W Birk
Apr 23, 2013·Gastroenterología y hepatología·Javier P GisbertJordi Sánchez-Delgado
Jan 15, 2013·Clinics and Research in Hepatology and Gastroenterology·Bilal ErgülSeyfettin Köklü
Sep 12, 2008·Helicobacter·Brian J EganColm O'Morain
Mar 1, 2012·Alimentary Pharmacology & Therapeutics·J P GisbertX Calvet
Dec 2, 2011·Alimentary Pharmacology & Therapeutics·J P Gisbert, X Calvet
Jun 28, 2016·Gastroenterología y hepatología·Javier P GisbertAdrián G McNicholl
Jan 1, 2009·Therapeutic Advances in Gastroenterology·Ulrich R M Bohr, Peter Malfertheiner
Dec 25, 2010·Therapeutic Advances in Gastroenterology·Javier P Gisbert
Oct 11, 2008·The Annals of Pharmacotherapy·Tomasz Z JodlowskiCharles R Ashby
Mar 23, 2017·Scandinavian Journal of Gastroenterology·Eva DoorakkersNele Brusselaers
Aug 2, 2016·Deutsches Ärzteblatt International·Joachim Mössner
Oct 2, 2021·Expert Opinion on Pharmacotherapy·Elias Xirouchakis, Sotirios D Georgopoulos

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.